![Ajan Reginald: Biotech Entrepreneur](https://colitco.com/wp-content/uploads/2023/02/thumbnail-sample-4.jpg)
Roquefort Therapeutics
Industry: BIOTECHNOLOGY
ROQUEFORT THERAPEUTICS PLC (LSE: ROQ) is a public company listed on the Main Market of the London stock exchange. Roquefort is a biotechnology company developing innovative cancer medicines in the high growth oncology market. Led by CEO AJAN REGINALD, Roquefort has portfolio of four pre-clinical anti-cancer drugs and 46 registered patents.
![Ajan Reginald: Biotech Entrepreneur](https://colitco.com/wp-content/uploads/2023/02/thumbnail-sample-4.jpg)
![Roquefort Therapeutics PLC (LSE: ROQ) and Randox Laboratories Strike Exclusive License Agreement for Medical Diagnostics](https://colitco.com/wp-content/uploads/2023/02/thumbnail-sample-3.jpg)
Roquefort Therapeutics PLC (LSE: ROQ) and Randox Laboratories Strike Exclusive License Agreement for Medical Diagnostics
![Roquefort Therapeutics Reports In-Vivo Safety for Midkine Oncology Antibodies](https://colitco.com/wp-content/uploads/2023/01/thuvbnm.jpg)
Roquefort Therapeutics Reports In-Vivo Safety for Midkine Oncology Antibodies
![Roquefort Therapeutics and CEO Ajan Reginald: An Inspiring Story](https://colitco.com/wp-content/uploads/2023/01/thumbnail-img.jpg)
Roquefort Therapeutics and CEO Ajan Reginald: An Inspiring Story
Disclaimer
COLITCO LLP accepts no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. COLITCO LLP or an associate may receive a commission for funds raised.